Abstract:Abstract In order to deploy virulence factors at appropriate times and locations, microbes must rapidly sense and respond to various metabolite signals. Previously we showed transient elevation of the methionine-derived metabolite methylthioadenosine (MTA) in serum during systemic Salmonella enterica serovar Typhimurium ( S. Typhimurium) infection. Here we explored the functional consequences of increased MTA concentrations on S. Typhimurium virulence. We found that MTA—but not other related metabolites involved in polyamine synthesis and methionine salvage—reduced motility, host cell pyroptosis, and cellular invasion. Further, we developed a genetic model of increased bacterial endogenous MTA production by knocking out the master repressor of the methionine regulon, metJ . Like MTA treated S. Typhimurium, the Δ metJ mutant displayed reduced motility, host cell pyroptosis, and invasion. These phenotypic effects of MTA correlated with suppression of flagellar and Salmonella pathogenicity island-1 (SPI-1) networks. Δ metJ S. Typhimurium had reduced virulence in oral infection of C57BL/6 mice. Finally, Δ metJ bacteria induced a less severe inflammatory cytokine response in a mouse sepsis model. These data provide a possible bacterial mechanism for our previous findings that pretreating mice with MTA dampens inflammation and prolongs survival. Together, these data indicate that exposure of S. Typhimurium to MTA or disruption of the bacterial methionine metabolism pathway is sufficient to suppress SPI-1 mediated processes, motility, and in vivo virulence. Significance Salmonella enterica serovar Typhimurium ( S . Typhimurium) is a leading cause of gastroenteritis and bacteremia worldwide. Widespread multi-drug resistance, inadequate diagnostics, and the absence of a vaccine for use in humans, all contribute to the global burden of morbidity and mortality associated with S. Typhimurium infection. Here we find that increasing the concentration of the methionine derived metabolite methylthioadenosine, either in S. Typhimurium or in its environment, is sufficient to suppress virulence processes. These findings could be leveraged to inform future therapeutic interventions against S. Typhimurium aimed at manipulating either host or pathogen methylthioadenosine production.

Myricetin Inhibits the Type III Secretion System of Salmonella Enterica Serovar Typhimurium by Downregulating the Salmonella Pathogenic Island I Gene Regulatory Pathway.

Quercitrin Is a Novel Inhibitor of Salmonella enterica Serovar Typhimurium Type III Secretion System

Proteomic Analysis of the Antimicrobial Effects of Sublethal Concentrations of Thymol on Salmonella Enterica Serovar Typhimurium

Harmine, an inhibitor of the type III secretion system of Salmonella enterica serovar Typhimurium

A small molecule, C24H17ClN4O2S, inhibits the function of the type III secretion system in Salmonella Typhimurium

Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system

Inhibition of the Type III Secretion System of Salmonella enterica Serovar Typhimurium via Treatment with Fraxetin

Design and Synthesis of 6-amido-3-carboxypyridazine Derivatives as Potent T3SS Inhibitors of Salmonella Enterica Serovar Typhimurium

The Herbal Compound Thymol Targets Multiple Salmonella Typhimurium Virulence Factors for Lon Protease Degradation

Identification of Novel Type Three Secretion System (T3SS) Inhibitors by Computational Methods and Anti-Salmonella Evaluations

Epigallocatechin gallate protects mice from Salmonella enterica ser. Typhimurium infection by modulating bacterial virulence through quorum sensing inhibition

Biofilm formation, antibiotic resistance, and genome sequencing of a unique isolate Salmonella Typhimurium M3

Antimicrobial Peptide JH-3 Effectively Kills Salmonella enterica Serovar Typhimurium Strain CVCC541 and Reduces Its Pathogenicity in Mice

Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice

A natural compound hyperoside targets Salmonella Typhimurium T3SS needle protein InvG

[Development of helical CT and clinical application].

The Antimicrobial Peptide Cathelicidin-Bf Could Be A Potential Therapeutic for Salmonella Typhimurium Infection

[Mechanism of the phosphoglucomutase reaction].

Identification of a Novel Salmonella Type III Effector by Quantitative Secretome Profiling.

Methylthioadenosine reduces host inflammatory response by suppressing Salmonella virulence

Application of inhibitors targeting the type III secretion system in phytopathogenic bacteria